The rapid evolution of psychedelic drug development is creating numerous regulatory challenges, from potential conditions of approval that can affect patient access to differences in federal and state policy regarding the drugs, according to authors of two newly published commentaries. One of the authors emphasized that public demand for psychedelics is far outpacing federal regulatory guidance. The articles were published online July 15, 2026 in JAMA Psychiatry and June 18, 2026 in the New England Journal of Medicine .
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: